Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Drug Discovery
IRBM, MD Anderson ink antibody development pact
by Rick Mullin
September 14, 2019
| A version of this story appeared in
Volume 97, Issue 36
IRBM has signed a service and development agreement with the University of Texas MD Anderson Cancer Center to develop monoclonal antibodies targeting a novel immune checkpoint. The two will combine their discovery technologies to identify and validate lead antibodies through preclinical proof of concept studies. IRBM will use its phage display antibody libraries and immuno-oncology capabilities to generate and optimize fully human antibody candidates against the undisclosed target.
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter